X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will enable Kimia to expand its ATLAS platform and pursue a broad range of therapeutic targets in oncology, immunology and inflammation.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: The Column Group
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 19, 2023
Details:
The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Product Name: CT-388
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Carmot Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger January 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
